Loading
A fund launched in 2022 that does for non-cancer medicines what the Cancer Drugs Fund does for cancer: pays for a promising but uncertain drug for a limited period while evidence is gathered, with the same budget of 340 million pounds.
United Kingdom (England), NHS funding scheme. NHS England and NICE launched the Innovative Medicines Fund in June 2022 with a budget of 340 million pounds, matching the Cancer Drugs Fund and giving a combined 680 million pounds of managed access funding a year. Primary text: the NHS England page and the fund's principles document.
How it works: as with the Cancer Drugs Fund, NICE can recommend a medicine for managed access when the evidence is too uncertain for a routine recommendation but the drug is plausibly cost-effective and further data collection can resolve the uncertainty; the medicine is funded for NHS patients for a defined period, data are collected, and NICE re-appraises. The fund applies to any non-cancer medicine, including gene therapies and medicines for rare diseases where trials are small, and it uses the same expenditure control mechanism that rebates companies if the budget is exceeded.
The arguments: the fund answered the long-standing complaint that the Cancer Drugs Fund favoured one disease area; sceptics questioned whether the NHS could collect useful evidence in two years for chronic conditions and whether the budget would be spent, since early uptake was slow. For oncology the fund matters as the model's extension and as evidence that managed access with data collection, rather than open-ended coverage, is the settled English approach to uncertainty.
Shares NICE technology appraisal methods (2022), NICE cancer guidance and technology appraisals (UK), Cancer Drugs Fund (England), Health technology assessment (HTA), reimbursement and QALYs and the tags law, uk.
Shares Weak real-world evidence and registries and the tags law, uk.
Shares the tags law, uk.
Shares Conditional marketing authorisation (EU), Health technology assessment (HTA), reimbursement and QALYs, Real-world evidence, Weak real-world evidence and registries and the tag law.
Shares Health technology assessment (HTA), reimbursement and QALYs, Real-world evidence, Weak real-world evidence and registries, Prices and value and the tag law.
Shares NICE technology appraisal methods (2022), Health technology assessment (HTA), reimbursement and QALYs, Prices and value and the tag law.
Shares NICE technology appraisal methods (2022), Health technology assessment (HTA), reimbursement and QALYs, Prices and value and the tag law.
Shares Real-world evidence, Weak real-world evidence and registries and the tag law.